Doses - RANITIDINE HCL

Dogs:

For esophagitis:
a) 1 - 2 mg/kg PO bid (Watrous 1988)
For chronic gastritis:
a) 0.5 mg/kg PO bid (Hall and Twedt 1988)
For ulcer disease:
a) 2 mg/kg PO q8h (Papich 1989)
b) 2 mg/kg PO, IV q8h (Matz 1995)
c) 0.5 mg/kg PO, IV bid (Chiapella 1988)
For gastrinoma:
a) 2 - 4 mg/kg PO bid (Lothrop 1989)
b) 0.5 mg/kg PO, IV or SQ bid (Kay, Kruth, and Twedt 1988)
To treat hypergastrinemia secondary to chronic renal failure:
a) 1 - 2 mg/kg PO bid (Morgan 1988)
To treat hyperhistaminemia secondary to mast cell tumors:
a) 2 mg/kg q12h (Fox 1995b)

Cats:

For ulcer disease:
a) 2.5 mg/kg IV q12h or 3.5 mg/kg PO q12h (Matz 1995), (Johnson 1996)

Horses:

a) 0.5 mg/kg bid PO (Robinson 1987)
b) Foals: 150 mg PO bid (Clark and Becht 1987)
c) 1 mg/kg q8h IV (Duran 1992)
Monitoring Parameters -
1) Clinical efficacy (dependent on reason for use); monitored by decrease in symptomatology, endoscopic examination, blood in feces, etc.
Client Information - To maximize the benefit of this medication, it must be administered asprescribed by the veterinarian; symptoms may reoccur if dosages are missed.
Dosage Forms/Preparations/FDA Approval Status/Withholding Times - Veterinary-Approved Products: None

Human-Approved Products:

Ranitidine HCl Tablets 75 mg, 150 mg, 300 mg (as base); Zantac® (Glaxo Wellcome); (Rx);
Zantac 75® (Glaxo Wellcome) (OTC)
Rantidine HCl Effervescent Tablets & Granules: 150 mg; Zantac EFFERdose® (Glaxo
Wellcome) (Rx)
Rantidine Capsules: 150 mg, 300 mg; Zantac GELdose® (Glaxo Wellcome) (Rx)Ranitidine HCl Oral Syrup 15 mg/ml in UD 10 ml and 480 ml; Zantac® (Glaxo Wellcome);(Rx); Rantidine HCl (UDL) (Rx)
Ranitidine HCl Injection: 0.5 mg/ml, 25 mg/ml in 100 ml single dose containers and 2, 10, & 40 ml vials and 2 ml syringes; Zantac® (Glaxo Wellcome) (Rx)
Ranitidine HCl 0.5 mg/ml (preservative free in 100ml single dose containers & 25 mg/ml (as
HCl) in 2 ml, 10 ml, & 40 ml vials; Zantac® (Glaxo); (Rx)